Qaelon Medical, a pioneer in real-time surgical leak detection and insufflation, and RevMedica, an innovator in surgical stapling solutions, are excited to announce a non-exclusive data partnership to improve stapler performance and clinical outcomes in gastrointestinal surgery.
Partnership Objectives
By integrating RevMedica’s advanced stapler technology with Qaelon’s real-time leak detection and performance data, the collaboration aims to:
- Accelerate product development and product validation.
- Assess the impact of varying tissue properties on staple line performance.
- Assist with regulatory approvals and claims development.
Thomas Wenchell, Chief Executive Officer, RevMedica: “Qaelon’s leak detection technology offers RevMedica objective insights to enhance the development of our tissue sensing technology and ultimately improve clinical outcomes. We’re excited about the potential this partnership brings to establish new performance benchmarks while supporting our mission to optimize decision-making in surgery.”
Also Read: Openwater Names Aaron Timm CEO Amid Rising Demand
Liam Burns, Chief Executive Officer, Qaelon Medical: “Our mission at Qaelon Medical is to address the devastating impact of surgical leaks. By joining forces with RevMedica, we have an opportunity to expand the impact of our life-saving technology while building on the surgical intelligence platform we recently announced with Caresyntax.”
Advancing Surgical Stapling with Quantifiable Leak Detection Data
RevMedica’s new Endo Stapling Platform provides digital precision and real-time feedback for minimally invasive procedures by optimizing staple formation and tissue management. Qaelon Medical’s unique solution provides real-time, quantifiable leak detection data that empowers surgeons to take immediate corrective action before the patient leaves the operating room. Both RevMedica and Qaelon Medical technologies have been selected for the FDA’s Safer Technologies Program (STeP), reserved for “medical devices that are reasonably expected to significantly improve the safety of currently available treatments.”
Source: PRNewswire